Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

In a world obsessed with youth, some scientists are turning

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

When Dr. Peter Marks walked out of the FDA’s headquarters

Forbion-Backed VectorY Therapeutics Raises $138M for ALS and Neurodegenerative Disease Research

Forbion-Backed VectorY Therapeutics Raises $138M for ALS and Neurodegenerative Disease Research

VectorY Therapeutics, a biotechnology company based in Amsterdam, Netherlands, has

AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development

AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development

AstraZeneca has completed its planned equity investment in Cellectis, a

€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?

€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?

From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough

From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough

Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy

Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

MOST POPULAR

News

AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Light-Based Microcapillary Monitoring Expands Precision in Biotechnology
Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Funding

Aging Science

Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show
New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging

Genomics

M&A & Partnerships

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion
Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion
Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top